AZYO Aziyo Biologics

Aziyo Biologics to Report Second Quarter 2022 Financial Results on August 11, 2022

Aziyo Biologics to Report Second Quarter 2022 Financial Results on August 11, 2022

SILVER SPRING, Md., July 28, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it will release second quarter 2022 financial results after market close on Thursday, August 11, 2022. Members of the Company’s management team will host a conference call and webcast with accompanying slides starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

Individuals interested in listening to the conference call are required to . Participants are required to register at least 15 minutes before the start of the call. A live and Archived webcast of the event will be available on the “investors” section of the Aziyo website at .

About Aziyo Biologics

Aziyo Biologics is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. Since its founding in 2015, the Company has created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties. For more information, visit .      

Media:

Courtney Guyer

Aziyo Biologics, Inc.

Investors:

Leigh Salvo

Gilmartin Group



EN
28/07/2022

Underlying

AZYOAziyo Biologics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aziyo Biologics

Jonathan Moreland
  • Jonathan Moreland
Free Trial
TPVG TRIPLEPOINT VEN...
GLP Global Partners... ... (+15)

InsiderInsights.com Daily Ratings Report: December 18, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
GLP GLOBAL PARTNERS LP
CRM SALESFORCE.COM INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
IGR CBRE CLARION GLOBAL REAL ESTAT
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
AZYO AZIYO BIOLOGICS
DLHC DALEIGH HOLDINGS CORP
IMNM IMMUNOME
PROP PRAIRIE OPERATING CO.
MXF THE MEXICO FUND
GF INC.
HYMC THE NEW GERMANY FUND
INC.
HYCROFT MINING HOLDING CORPORATION
16h / 58m 16h / 58m 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Millio...

Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development - Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financ...

November 6, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Report Third Quarter 2025 Financial Results on Thursday, Nov...

Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 GAITHERSBURG, Md., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following informati...

October 23, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday...

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21 GAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XIX Conference in San Diego on Tuesday, October 21, 2025, at 1:00 p.m. PT (4:00 p.m. ET). LD Micro Main Event XIX ConferencePresentation Date: Tuesday, October 21, 2025Presentation Time: 1:00 p.m. PT (4:00 p.m. ET)Webcast:  Elutia management will also...

October 14, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board o...

Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, announced the appointment of Guido J. Neels to the Company’s Board of Directors. Mr. Neels will also serve as a member of the audit committee of the Board. In conjunction with Mr. Neels’ appointment, W. Matthew Zuga and Maybelle Jordan have bo...

October 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch